TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03496402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling on blood, bone marrow and cerebrospinal fluid
Description: biological sampling during treatment and follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling on blood, bone marrow and cerebrospinal fluid
Description: biological sampling during treatment and follow-up
Study: NCT00896636

Intervention type: OTHER
Intervention: Mammogram
Description: Standard mammography of both breasts to obtain images for breast density measurement.

Intervention type: OTHER
Intervention: Mammogram
Description: Standard mammography of both breasts to obtain images for breast density measurement.
Study: NCT00766961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-catheter arterial embolization
Description: Trans-catheter arterial embolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery
Study: NCT03680430

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiation therapy
Description: Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
Study: NCT03412071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tinidazole
Description: Please see description under arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical metronidazole
Description: Please see description under arms
Study: NCT02095522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03685617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Chamber Pacemaker
Description: 1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His Bundle Pacemaker
Description: 1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
Study: NCT01897077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Dissolving Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Dissolving Film
Study: NCT04417439

Intervention type: OTHER
Intervention: universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)
Description: The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.

Intervention type: OTHER
Intervention: universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)
Description: The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.

Intervention type: OTHER
Intervention: universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)
Description: The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
Study: NCT03610386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adding menthoxypropanediol to the biopsy
Description: Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...). One of the two biopsies will receive menthoxypropanediol topically.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No adding menthoxypropanediol to the biopsy
Description: Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...). One of the two biopsies will not receive menthoxypropanediol.
Study: NCT04439123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO
Study: NCT03412071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Clindamycin
Description: Please see description under arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Hydrogen Peroxide
Description: Please see description under arms
Study: NCT00995865

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: XRX-001 Inactivated yellow fever vaccine
Description: Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: XRX-001 Inactivated yellow fever vaccine
Description: Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl Injectable 0.9%
Study: NCT02653027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Description: Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT
Description: A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
Study: NCT04263454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin, Escherichia Coli
Description: Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.

Intervention type: DRUG
Group type: OTHER
Intervention: Endotoxin, Escherichia Coli
Description: Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy
Description: MRI is a non-invasive imaging technique and does not utilize ionizing radiation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Spectroscopy
Description: MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
Study: NCT01674634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XIAFLEX / XIAPEX
Description: injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])
Study: NCT01473056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853
Description: Tablets, twice a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 JTK-853
Description: Tablets, twice a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3 JTK-853
Description: Tablets, three times a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4 JTK-853
Description: Tablets, twice a day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, twice a day or three times a day for 3 days
Study: NCT05591846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Description: Face-to-face training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Description: Face-to-face training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based training
Description: web-based training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based training
Description: web-based training
Study: NCT01003444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
Study: NCT01277510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet capsule
Description: Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets and capsules for sprinkling identical to active treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
Study: NCT04374877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-388
Description: CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-388
Description: CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-388
Description: CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
Study: NCT01277510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
Study: NCT03670758

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein S activity
Description: Intravenous blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein S activity
Description: Intravenous blood sample
Study: NCT04262245

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Irrigation
Description: irrigation with syringe

Intervention type: DEVICE
Group type: OTHER
Intervention: Xp-endo Finisher (XPF)
Description: irrigation activation file

Intervention type: DEVICE
Group type: OTHER
Intervention: Passive Ultrasonic Irrigation
Description: irrigation activation method

Intervention type: DEVICE
Group type: OTHER
Intervention: EndoActivator
Description: irrigation activation method
Study: NCT04374877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-388
Description: CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
Study: NCT00885898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive-ventilation
Description: increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
Study: NCT02025517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Tasks.
Description: The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
Study: NCT01762046

Intervention type: DRUG
Group type: OTHER
Intervention: Glipizide
Study: NCT04337658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT00885898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: oxygen, diuretics, bronchodilators, positive inotropic drugs
Study: NCT00124657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride
Description: This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
Study: NCT01456403

Intervention type: OTHER
Intervention: Histological validation
Description: 3D ultrasound, PET/CT, MRI, contrast ultrasound
Study: NCT03410771

Intervention type: DRUG
Intervention: Monitor antibiotic exposure (PK profile)
Description: several plasma samples to measure drug exposure
Study: NCT04374877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab by intravenous (IV) infusion
Study: NCT03410771

Intervention type: DRUG
Intervention: Monitor antibiotic exposure (PK profile)
Description: several plasma samples to measure drug exposure

Intervention type: DRUG
Intervention: Monitor antibiotic exposure (PK profile)
Description: several plasma samples to measure drug exposure

Intervention type: DRUG
Intervention: Monitor antibiotic exposure (PK profile)
Description: several plasma samples to measure drug exposure

Intervention type: DEVICE
Intervention: Bioelectrical impedance analysis to measure body composition
Description: non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.

Intervention type: DEVICE
Intervention: Bioelectrical impedance analysis to measure body composition
Description: non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.

Intervention type: DEVICE
Intervention: Bioelectrical impedance analysis to measure body composition
Description: non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.

Intervention type: DEVICE
Intervention: Bioelectrical impedance analysis to measure body composition
Description: non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
Study: NCT04321031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet
Study: NCT04337658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT04321031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet
Study: NCT04374877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab by IV infusion
Study: NCT02535338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib Lactate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01762046

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Glucose Tolerance Test
Study: NCT03702686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEEDBACK System
Description: Smart Nipple Shield and Monitor Unit
Study: NCT02323932

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perception of correct intonation identification
Description: The amount of change in the fundamental frequency that was required in order to identify a question

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perception of correct intonation identification
Description: The amount of change in the fundamental frequency that was required in order to identify a question
Study: NCT01721473

Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan

Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan

Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan

Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan

Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan

Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan
Study: NCT02701842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImPACT Online/Paper Pencil Tests

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ImPACT Online
Study: NCT01338142

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CCC
Description: 600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACC
Description: 600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection